Simlukafusp alfa

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Simlukafusp alfa (FAP-IL2v) 是一种免疫细胞因子，包括一种抗成纤维细胞活化蛋白 α (FAPα) 的抗体和一种只结合 IL-2Rβγ 的 IL-2 变体。Simlukafusp alfa 是一种人 IgG1 抗体。

Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1.

Cell Proliferation AssayCell Line:NK cells, CD4+ and CD8+ T cells Concentration:0-100 nM Incubation Time:5 days Result:Induced a dose-dependent proliferation of resting NK cells and resting and activated CD4+ and CD8+ T cells within peripheral blood mononuclear cells (PBMCs).

Animal Model:huCD16-transgenic SCID mice, lung orthotopic xenograft A549 modelDosage:1 mg/kg in combination with 25 mg/kg Cetuximab (HY-P9905) as single agentsAdministration:IV, weekly starting at Day 14 for 4 weeks Result:Achieved greater tumor control than either agent given as monotherapy. Reduced tumor volume and tumor growth.Animal Model:CD-1 mice Dosage:1, 2 or 4 mg/kg Administration:IV (Pharmacokinetic Analysis) Result:Pharmacokinetic parameters after first dose of human FAP-IL2v (huFAP-IL2v) in CD-1 miceCD-1 mice (n=10 per group) were given 1, 2, and 4 mg/kg huFAP-IL2v by IV administration once weekly. Multiple IV doses at 1 and 2 mg/kg were administered QW for up to a maximum of three doses, at which point toxicity was observed. Only a single dose was administered to the 4-mg/kg IV treatment group because of toxicity in these treatment groups. Blood was sampled at 0.5, 6, 24, 48, 72, and 168 h. AUC0-168h, area under the concentration-time curve from 0 to 168 hours; Cmax, maximum serum concentration observed; CL, total clearance; FAP-IL2v, fibroblast activation protein-α -targeted interleukin 2 variant (IL2v) immunocytokine; hu, humanized; IV, intravenous.

——

Others

Other Targets

Interleukin

——

——

1776942-10-9

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years